Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.
US FDA says Lilly's weight-loss drug no longer in shortage
Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration's website showed on Wednesday.
Weight Loss From GLP-1 Drugs Not As Robust In Real-World Settings
In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.
How biospecimens are advancing the development of weight loss drugs
Explore how pharmaceutical researchers are fueling weight loss drug development using biospecimens to unlock the underlying mechanisms of obesity.
England's NHS to offer Lilly's weight-loss drug to some patients
England's National Health Services will offer Eli Lilly's weight-loss drug to nearly a quarter million people as part of a three-year plan, the country's drugs cost regulator said on Thursday. The drug,
Eli Lilly’s weight-loss drugs no longer in shortage, FDA says
Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug Zepbound, can now meet present and projected national demand, the FDA said in a statement.
Lilly's weight-loss, diabetes drugs no longer in shortage, pressuring Hims and Hers' stock
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding manufacturing.
England’s NHS to Offer Eli Lilly Obesity Drug to Some Patients
Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years as part of a phased rollout of the popular drug.
Lilly's weight-loss drug removed from FDA's shortage list
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on firms selling cheaper versions known as compounded drugs.
Facebook has become the place to sell leftover Ozempic, other weight loss drugs — as NYC sellers take advantage of shortages and high prices
God knows what volume they’re actually selling. And who knows? You’re just taking it,” one expert told The Post.
Zepbound is no longer in shortage. That could hurt off-brand weight loss drug sellers
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...
What Is the Ideal Fat-Burning Heart Rate for Weight Loss?
A trainer shares valuable insights on the ideal fat-burning heart rate for weight loss from years of helping clients achieve ...
England's NHS to offer Lilly's weight-loss drugs to some patients
England's National Health Services plans to offer Eli Lilly's weight-loss drugs to nearly a quarter million people as part of ...
Trying to Lose Weight? Here are 5 Ways Drinking More Water Could Help
Does drinking water help you lose weight? Believe it or not, it can. While this might sound too good to be true, there’s some ...
How Long Do You Need to Work Out To See Weight Loss Results?
Fitness experts reveal how long you need to work out to start seeing weight loss progress and the ideal forms of training to focus on.
Christina Aguilera continues to spark fan concern with dramatic weight loss: ‘She’s too thin’
The “Genie in a Bottle” singer visited Barry’s gym in West Hollywood, Calif., to celebrate the 25th anniversary of her ...
Weight-loss medication firm weighs in on impact of port strike
Ahara CEO and co-founder Julie Wainwright discusses the company's rush to develop weight loss drugs and the impact of the ...